Ronald Brus resigns from the Galapagos Board
Galapagos NV announced that Dr Ronald Brus has resigned from the Board of Directors.
Ronald Brus is President and Chief Executive Officer of Crucell. Dr Brus was a member of the Galapagos Board of Directors from 2000 until Galapagos' IPO in May 2005 and later rejoined the Board in April 2010. In February 2011, Crucell was acquired by Johnson & Johnson. Corporate policies at Johnson & Johnson stipulate that managers cannot serve as a member of any Board of Directors, and therefore Dr Brus resigned from Galapagos' Board effective 25 May 2011.
"We thank Ronald again for his contribution as a Board member," said Onno van de Stolpe, CEO of Galapagos. "Ronald has been involved with Galapagos from the start, and we have benefited from his strategic insights and experience as a successful biotech CEO. We wish him the best within Johnson & Johnson."
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.